Oarsman Capital Inc. Purchases 45 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Oarsman Capital Inc. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,387 shares of the pharmaceutical company’s stock after acquiring an additional 45 shares during the period. Oarsman Capital Inc.’s holdings in Vertex Pharmaceuticals were worth $1,953,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Advisor OS LLC lifted its stake in Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after acquiring an additional 23 shares in the last quarter. Costello Asset Management INC increased its position in shares of Vertex Pharmaceuticals by 3.6% during the 2nd quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company’s stock worth $307,000 after purchasing an additional 24 shares during the last quarter. Avidian Wealth Enterprises LLC increased its position in shares of Vertex Pharmaceuticals by 2.1% during the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock worth $594,000 after purchasing an additional 25 shares during the last quarter. Strategic Blueprint LLC increased its position in shares of Vertex Pharmaceuticals by 1.7% during the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock worth $726,000 after purchasing an additional 25 shares during the last quarter. Finally, Newman Dignan & Sheerar Inc. increased its position in shares of Vertex Pharmaceuticals by 3.3% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock worth $350,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.5%

VRTX stock opened at $422.39 on Wednesday. The firm has a market capitalization of $108.30 billion, a PE ratio of 30.19 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The business’s 50 day simple moving average is $400.19 and its 200 day simple moving average is $433.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same period in the prior year, the firm posted ($12.83) EPS. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at $17,535,600. This represents a 12.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on VRTX shares. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They set a “market perform” rating on the stock. Morgan Stanley lowered their price target on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Canaccord Genuity Group lowered their price target on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $494.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.